1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Woodcock: High Prices Create Problems For Entire Accelerated Approval Program

 
• By Sarah Karlin-Smith

Acting FDA commissioner suggests a primary reason for outrage over accelerated approvals is the high costs of certain medications despite their unproven clinical benefits, an issue that is outside of the agency’s purview. Health policy experts says FDA shouldn’t be left off the hook that easily.

price tag
High price tags are leading to opposition to FDA’s accelerated approval program, Woodcock says • Source: Alamy

“Much of the debate,” around the US Food and Drug Administration’s accelerated approval program is not driven by the questions surrounding treatments’ risks and benefits but is instead spurred by “the larger societal trade off of the high prices for these agents,” FDA Acting Commissioner Janet Woodcock said in response to complaints around accelerated approval and whether she believes the program is ripe for reform or working as intended.

“Those perceived price tags don't just raise eyebrows, they create opposition to the entire program,” Woodcock said in a late...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

US FDA Begins ‘Competitive Search’ For New Drugs Center Director

 
• By Derrick Gingery and Sarah Karlin-Smith

The FDA deputy commissioner emailed staff asking anyone interested in the position to send her their curriculum vitae, an unusual method for finding candidates for a high-level position.

Pink Sheet Podcast: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors explain Tidmarsh’s abrupt resignation as the FDA’s chief drug regulator and the potential impact on the already reeling agency.

FDA Office of New Drugs Director Mary Thanh Hai Not Interested In CDER Director Job

 
• By Sue Sutter

The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.

More from Agency Leadership

US FDA’s Richard Pazdur Says ‘No’ To CDER Director’s Spot

 
• By Sue Sutter, Sarah Karlin-Smith, and Derrick Gingery

Center for Drug Evaluation and Research staff continue to wait for a replacement for George Tidmarsh, who resigned Nov. 2 after less than four months in the position.

Australia’s Tony Lawler Takes Charge of International Regulatory Coalition

 
• By Neena Brizmohun

Lawler, who leads the Therapeutic Goods Administration, has replaced the European Medicines Agency’s Emer Cooke as chair of the International Coalition of Medicines Regulatory Authorities.

Tidmarsh Creates More Instability And Uncertainty For US FDA, Industry

 
• By Sarah Karlin-Smith

The issues surrounding the FDA's Center for Drug Evaluation and Research director are raising new concerns about more career staff attrition, which likely will negatively impact the drug industry.